OncoSec Medical Inc (ONCSQ)

[Titan V]

The biomarker assay is currently being used to select patients for the ongoing Phase II clinical trial evaluating the combination of OncoSec's ImmunoPulse IL-12 and pembrolizumab in melanoma patients. We're using the assay's ability to select patients, who are unlikely to respond to anti-PD-1, and enroll these patients in our Phase II combination trial. Data from this trial is expected to be presented in 2016.

Thanks for sharing chickpea598. Given the peer-reviewed best in class accuracy of OncoSec's biomarker assay, if the data this fall shows that absolute non-responders became responders to Keytruda, ONCS share price will move in an epic way IMO.